HSBC TUR.WAR.OP.END. CPW/ DE000HG97QY9 /
| 5/29/2024 1:35:46 PM | Chg.0.0000 | Bid3:21:43 PM | Ask3:21:43 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 2.0500EUR | 0.00% | 1.9900 Bid Size: 10,000 |
2.1100 Ask Size: 10,000 |
Check Point Software... | 127.893 USD | 12/31/2078 | Call |
GlobeNewswire
3:00 PM
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
GlobeNewswire
3:00 PM
Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of Launch
GlobeNewswire
3:00 PM
Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immuno...
GlobeNewswire
2:00 PM
Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Ph...
GlobeNewswire
2:00 PM
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology...
GlobeNewswire
2:00 PM
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
GlobeNewswire
1:00 PM
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KI...
GlobeNewswire
12:30 PM
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR ...
GlobeNewswire
8:00 AM
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
GlobeNewswire
5/28
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual ...
GlobeNewswire
5/28
7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with...
GlobeNewswire
5/28
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkp...
GlobeNewswire
5/28
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Tril...
GlobeNewswire
5/28
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
GlobeNewswire
5/27
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel...
GlobeNewswire
5/27
CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. ...
GlobeNewswire
5/24
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenaden...
GlobeNewswire
5/23
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-10...
GlobeNewswire
5/23
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upco...
GlobeNewswire
5/23
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at A...
GlobeNewswire
5/23
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Adva...
GlobeNewswire
5/23
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study i...
